Summary:The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but who had a significant risk of later developing clinical VOD. In January 1994 we began to treat patients who developed Susp VOD with tPA rather than waiting until they developed clinical VOD. We now report on the results of the first 37 patients who ultimately developed clinical VOD and received tPA therapy prior to Susp VOD, or at the time they had established VOD. Significant bleeding complications occurred in 13 (35%) patients but resolved with discontinuation of therapy in all but one. We found that patients treated early in the course of hepatotoxicity prior to the development of overt VOD had a significantly higher response rate and 100 day survival than patients treated at the time of established VOD. Given the poor results seen in treating late VOD, we suggest that early treatment with tPA may improve the outcome in patients who develop signs of hepatotoxicity following marrow transplantation. Keywords: tissue plasminogen activator; hepatotoxicity; bone marrow transplant Hepatic veno-occlusive disease (VOD) is a frequent and serious complication of bone marrow transplantation (BMT). Published reports indicate an incidence of 5-50%, and a mortality as high as 15% depending on the clinical series and the definition used.1-4 Clinically, VOD has been defined as hyperbilirubinemia within the first 4 weeks following BMT, with associated findings of ascites, unexplained weight gain, hepatomegaly or right upper quadrant pain. VOD is characterized histologically, by necrosis of zone 3 hepatocytes and deposition of fibrin and factor VIII in hepatic venules. These findings suggest a role of the coagulation system in the pathophysiology of VOD. sparse, and treatment options are limited. Despite the paucity of data, early experience with tissue plasminogen activator (tPA) is encouraging. Presently, tPA represents the most promising therapy for the treatment of hepatotoxicity following BMT. [6][7][8][9] Based on the promising initial reports of Bearman et al, 9 we began to treat patients with established VOD with tPA in April 1993. Our early experience in treating patients with advanced VOD using tPA was unfavorable, as in the larger trial recently reported by Bearman and colleagues.10 Others had suggested that successful treatment required early therapy.11 Thus in January 1994 we began to treat patients when they developed persistent unexplained hyperbilirubinemia (suspected VOD) without additional clinical evidence of VOD. To investigate whether earlier treatment may influence the course of hepatotoxicity, we examined only those patients who developed clinical VOD, and compared the results for those who received tPA prior to or after developing clinical VOD. Methods Patient selection and hepato...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.